Tumorigenic potential and disease manifestations of malignant B-cell variants differing in their fibronectin adhesiveness

Experimental Hematology

Volumn 36, Issue 11, 2008, Pages 1524-1534

  Nadav, Liat ^a,b   Kalchenko, Vyacheslav ^a   Barak, Meir Max ^a   Naparstek, Elizabeth ^b,c   Geiger, Benjamin ^a   Katz, Ben Zion ^b,c  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRONECTIN; FLUORESCENT DYE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE; BONE LESION; BONE MARROW; BONE MARROW CELL; CANCER CELL; CANCER RESISTANCE; CARCINOGENICITY; CELL ADHESION; CELL DIFFERENTIATION; CELL GROWTH; CELL HOMING; CELL LINEAGE; CELL MIGRATION; CELL POPULATION; CELL PROLIFERATION; CELL SURFACE; CELL TYPE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE MARKER; DRUG EFFECT; FEMALE; HISTOPATHOLOGY; IN VITRO STUDY; INOCULATION; LIVER; MOUSE; MULTIPLE MYELOMA; NONHUMAN; NONOBESE DIABETIC MOUSE; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEIN ISOLATION; SCID MOUSE; SPLEEN; TUMOR GROWTH; WHOLE BODY IMAGING; ANIMAL; EXPERIMENTAL NEOPLASM; MICRO-COMPUTED TOMOGRAPHY; MOUSE MUTANT; OSTEOLYSIS; PATHOLOGY; PHYSIOLOGY;

MUS;

ANIMALS; B-LYMPHOCYTES; CELL ADHESION; FIBRONECTINS; MICE; MICE, INBRED NOD; MICE, SCID; MULTIPLE MYELOMA; NEOPLASMS, EXPERIMENTAL; OSTEOLYSIS; X-RAY MICROTOMOGRAPHY;

EID: 53749092157     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2008.05.009     Document Type: Article

References (35)

1. Ramiro A.R., Nussenzweig M.C., and Nussenzweig A. Switching on chromosomal translocations. Cancer Res 66 (2006) 7837-7839
2. Gonzalez D., van der Burg M., Garcia-Sanz R., et al. Immunoglobulin gene rearrangements and the pathogenesis of multiple myeloma. Blood 110 (2007) 3112-3121
3. Epeldegui M., Widney D.P., and Martinez-Maza O. Pathogenesis of AIDS lymphoma: role of oncogenic viruses and B cell activation-associated molecular lesions. Curr Opin Oncol 18 (2006) 444-448
4. Young L.S., and Rickinson A.B. Epstein-Barr virus: 40 years on. Nat Rev Cancer 4 (2004) 757-768
5. Kuppers R. Mechanisms of B-cell lymphoma pathogenesis. Nat Rev Cancer 5 (2005) 251-262
6. Munk Pedersen I., and Reed J. Microenvironmental interactions and survival of CLL. B-cells. Leuk Lymphoma 45 (2004) 2365-2372
7. Mitsiades C.S., Mitsiades N.S., Munshi N.C., Richardson P.G., and Anderson K.C. The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: interplay of growth factors, their receptors and stromal interactions. Eur J Cancer 42 (2006) 1564-1573
8. Pagnucco G., Cardinale G., and Gervasi F. Targeting multiple myeloma cells and their bone marrow microenvironment. Ann N Y Acad Sci 1028 (2004) 390-399
9. Roccaro A.M., Hideshima T., Raje N., et al. Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells. Cancer Res 66 (2006) 184-191
10. Ng M.H. Death associated protein kinase: from regulation of apoptosis to tumor suppressive functions and B cell malignancies. Apoptosis 7 (2002) 261-270
11. Ria R., Vacca A., Ribatti D., Di Raimondo F., Merchionne F., and Dammacco F. Alpha(v)beta(3) integrin engagement enhances cell invasiveness in human multiple myeloma. Haematologica 87 (2002) 836-845
12. Garcia-Gila M., Lopez-Martin E.M., and Garcia-Pardo A. Adhesion to fibronectin via alpha4 integrin (CD49d) protects B cells from apoptosis induced by serum deprivation but not via IgM or Fas/Apo-1 receptors. Clin Exp Immunol 127 (2002) 455-462
13. Hazlehurst L.A., and Dalton W.S. Mechanisms associated with cell adhesion mediated drug resistance (CAM-DR) in hematopoietic malignancies. Cancer Metastasis Rev 20 (2001) 43-50
14. Lengauer C., Kinzler K.W., and Vogelstein B. Genetic instabilities in human cancers. Nature 396 (1998) 643-649
15. Yang M.H., Yen C.C., Chiang S.C., et al. Prognostic significance of clonal diversity of immunoglobulin gene rearrangements in patients with diffuse large B-cell lymphoma. Oncol Rep 13 (2005) 503-508
16. Nadav L., Katz B.Z., Baron S., Cohen N., Naparstek E., and Geiger B. The generation and regulation of functional diversity of malignant plasma cells. Cancer Res 66 (2006) 8608-8616
17. Zhu D., Orchard J., Oscier D.G., Wright D.H., and Stevenson F.K. V(H) gene analysis of splenic marginal zone lymphomas reveals diversity in mutational status and initiation of somatic mutation in vivo. Blood 100 (2002) 2659-2661
18. Kalchenko V., Shivtiel S., Malina V., et al. Use of lipophilic near-infrared dye in whole-body optical imaging of hematopoietic cell homing. J Biomed Opt 11 (2006) 050507
19. Damiano J.S., Cress A.E., Hazlehurst L.A., Shtil A.A., and Dalton W.S. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood 93 (1999) 1658-1667
20. Redondo-Munoz J., Escobar-Diaz E., Samaniego R., Terol M.J., Garcia-Marco J.A., and Garcia-Pardo A. MMP-9 in B-cell chronic lymphocytic leukemia is up-regulated by alpha4beta1 integrin or CXCR4 engagement via distinct signaling pathways, localizes to podosomes, and is involved in cell invasion and migration. Blood 108 (2006) 3143-3151
21. de la Fuente M.T., Casanova B., Moyano J.V., et al. Engagement of alpha4beta1 integrin by fibronectin induces in vitro resistance of B chronic lymphocytic leukemia cells to fludarabine. J Leukoc Biol 71 (2002) 495-502
22. Huang Y.W., Richardson J.A., Tong A.W., Zhang B.Q., Stone M.J., and Vitetta E.S. Disseminated growth of a human multiple myeloma cell line in mice with severe combined immunodeficiency disease. Cancer Res 53 (1993) 1392-1396
23. Corre J., Mahtouk K., Attal M., et al. Bone marrow mesenchymal stem cells are abnormal in multiple myeloma. Leukemia 21 (2007) 1079-1088
24. Perez L.E., Parquet N., Shain K., et al. Bone marrow stroma confers resistance to Apo2 ligand/TRAIL in multiple myeloma in part by regulating c-FLIP. J Immunol 180 (2008) 1545-1555
25. Hecht M., von Metzler I., Sack K., Kaiser M., and Sezer O. Interactions of myeloma cells with osteoclasts promote tumour expansion and bone degradation through activation of a complex signalling network and upregulation of cathepsin K, matrix metalloproteinases (MMPs) and urokinase plasminogen activator (uPA). Exp Cell Res 314 (2008) 1082-1092
26. Vande Broek I., Vanderkerken K., Van Camp B., and Van Riet I. Extravasation and homing mechanisms in multiple myeloma. Clin Exp Metastasis 25 (2008) 325-334
27. Vanderkerken K., De Greef C., Asosingh K., et al. Selective initial in vivo homing pattern of 5T2 multiple myeloma cells in the C57BL/KalwRij mouse. Br J Cancer 82 (2000) 953-959
28. Dhodapkar M.V., Weinstein R., Tricot G., et al. Biologic and therapeutic determinants of bone mineral density in multiple myeloma. Leuk Lymphoma 32 (1998) 121-127
29. Abildgaard N., Brixen K., Eriksen E.F., Kristensen J.E., Nielsen J.L., and Heickendorff L. Sequential analysis of biochemical markers of bone resorption and bone densitometry in multiple myeloma. Haematologica 89 (2004) 567-577
30. Teoh G., and Anderson K.C. Interaction of tumor and host cells with adhesion and extracellular matrix molecules in the development of multiple myeloma. Hematol Oncol Clin North Am 11 (1997) 27-42
31. Silvestris F., Cafforio P., Calvani N., De Matteo M., Lombardi L., and Dammacco F. In-vitro functional phenotypes of plasma cell lines from patients with multiple myeloma. Leuk Lymphoma 47 (2006) 1921-1931
32. Weinstat-Saslow D.L., Zabrenetzky V.S., VanHoutte K., Frazier W.A., Roberts D.D., and Steeg P.S. Transfection of thrombospondin 1 complementary DNA into a human breast carcinoma cell line reduces primary tumor growth, metastatic potential, and angiogenesis. Cancer Res 54 (1994) 6504-6511
33. Rak J.W., and Kerbel R.S. Growth advantage ("clonal dominance") of metastatically competent tumor cell variants expressed under selective two- or three-dimensional tissue culture conditions. In Vitro Cell Dev Biol Anim 29A (1993) 742-748
34. Mori Y., Shimizu N., Dallas M., et al. Anti-alpha4 integrin antibody suppresses the development of multiple myeloma and associated osteoclastic osteolysis. Blood 104 (2004) 2149-2154
35. Damiano J.S. Integrins as novel drug targets for overcoming innate drug resistance. Curr Cancer Drug Targets 2 (2002) 37-43